Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 24, 2026, 5:51 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: System Lupus Erythematosus(SLE) Clear all
Terminated Early Phase 1 Interventional

COVID-19 Vaccination in Rheumatic Disease Patients

NCT04839315
View directory record Official record
Conditions
Systemic Lupus Erythematosus, Sjogren's Syndrome, Inflammatory Myositis, Psoriatic Arthritis, Gout, Ankylosing Spondylitis, Arthritis of Multiple Sites Associated With Inflammatory Bowel Disease (Diagnosis), Osteoarthritis
Interventions
mRNA COVD19 vaccine
Biological
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
58 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jun 2, 2022 · Synced Jul 24, 2026, 5:51 AM EDT
Terminated Not applicable Interventional Accepts healthy volunteers Results available

Acupressure for Fatigue in Systemic Lupus Erythematosus

NCT03200548
View directory record Official record
Conditions
Fatigue, Lupus Erythematosus, Systemic, Pain, Chronic, Quality of Life, Sleep
Interventions
Relaxing acupressure plus usual care, Usual care, Stimulating acupressure plus usual care, Sham acupressure plus usual care
Behavioral
Lead sponsor
Suzanna Zick
Other
Eligibility
18 Years and older · Female only
Enrollment
52 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2019
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated May 11, 2023 · Synced Jul 24, 2026, 5:51 AM EDT
Completed Not applicable Interventional

Lupus Walking Intervention to Address Fatigue/Quality of Life

NCT07481214
View directory record Official record
Conditions
System Lupus Erythematosus(SLE)
Interventions
guided increases in daily walking
Behavioral
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
101 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Apr 12, 2026 · Synced Jul 24, 2026, 5:51 AM EDT
Terminated Phase 3 Interventional

Study of Epratuzumab in Systemic Lupus Erythematosus (SLE)

NCT00383214
View directory record Official record
Conditions
Systemic Lupus Erythematosus
Interventions
Epratuzumab, Placebo
Drug · Other
Lead sponsor
UCB Pharma
Industry
Eligibility
18 Years and older
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
25
States / cities
Birmingham, Alabama • Tucson, Arizona • Los Angeles, California + 22 more
Source: ClinicalTrials.gov public record
Updated Jun 6, 2012 · Synced Jul 24, 2026, 5:51 AM EDT
Completed Phase 2 Interventional

Study of Epratuzumab in Serologically-positive Systemic Lupus Erythematosus (SLE) Patients With Active Disease

NCT00624351
View directory record Official record
Conditions
Systemic Lupus Erythematosus
Interventions
Epratuzumab, Placebo
Biological · Other
Lead sponsor
UCB Pharma
Industry
Eligibility
18 Years and older
Enrollment
227 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
19
States / cities
Birmingham, Alabama • Tucson, Arizona • La Jolla, California + 16 more
Source: ClinicalTrials.gov public record
Updated Sep 11, 2011 · Synced Jul 24, 2026, 5:51 AM EDT
Completed Phase 1Phase 2 Interventional

Phase 1b/2a Study to Evaluate Safety and Efficacy of KPG-818 in SLE

NCT04643067
View directory record Official record
Conditions
SLE; Drug
Interventions
KPG-818 low dose, KPG-818 mid dose, KPG-818 high dose, Placebo
Drug
Lead sponsor
Kangpu Biopharmaceuticals, Ltd.
Industry
Eligibility
18 Years and older
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
18
States / cities
Anniston, Alabama • Birmingham, Alabama • Clearwater, Florida + 12 more
Source: ClinicalTrials.gov public record
Updated May 22, 2024 · Synced Jul 24, 2026, 5:51 AM EDT
Active, not recruiting Phase 3 Interventional

Safety, Efficacy and Tolerability of Ianalumab Versus Placebo, Combination With SoC Therapy, in Participants With Active Lupus Nephritis

NCT05126277
View directory record Official record
Conditions
Lupus Nephritis
Interventions
ianalumab s.c. q4w, ianalumab s.c. q12w, placebo s.c.
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 100 Years
Enrollment
452 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2031
U.S. locations
27
States / cities
Birmingham, Alabama • La Palma, California • Orange, California + 21 more
Source: ClinicalTrials.gov public record
Updated May 21, 2026 · Synced Jul 24, 2026, 5:51 AM EDT
Completed Phase 1Phase 2 Interventional Results available

A Study of DS-7011a in Patients With Systemic Lupus Erythematosus

NCT05638802
View directory record Official record
Conditions
Systemic Lupus Erythematosus
Interventions
DS-7011a, Placebo
Drug
Lead sponsor
Daiichi Sankyo
Industry
Eligibility
18 Years and older
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
12
States / cities
Anniston, Alabama • North Little Rock, Arkansas • North Miami Beach, Florida + 9 more
Source: ClinicalTrials.gov public record
Updated May 27, 2026 · Synced Jul 24, 2026, 5:51 AM EDT
Not listed Phase 3 Interventional

Study of GL701 in Men With Systemic Lupus Erythematosus

NCT00037128
View directory record Official record
Conditions
Systemic Lupus Erythematosus
Interventions
GL701
Drug
Lead sponsor
Genelabs Technologies
Industry
Eligibility
18 Years and older · Male only
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1998
U.S. locations
1
States / cities
Redwood City, California
Source: ClinicalTrials.gov public record
Updated Jun 23, 2005 · Synced Jul 24, 2026, 5:51 AM EDT
Completed Phase 1 Interventional

A Study of AMG 557 in Adults With Systemic Lupus Erythematosus

NCT00774943
View directory record Official record
Conditions
Systemic Lupus Erythematosus
Interventions
AMG 557
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years to 70 Years
Enrollment
58 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
11
States / cities
Anniston, Alabama • Phoenix, Arizona • San Leandro, California + 8 more
Source: ClinicalTrials.gov public record
Updated Apr 8, 2013 · Synced Jul 24, 2026, 5:51 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Single Ascending Dose Study in Healthy Participants and Multiple Dose Study of JNJ-55920839 in Participants With Mild to Moderate Systemic Lupus Erythematosus

NCT02609789
View directory record Official record
Conditions
Systemic Lupus Erythematosus, Healthy
Interventions
JNJ-55920839, Placebo
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years to 55 Years
Enrollment
72 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2018
U.S. locations
3
States / cities
Birmingham, Alabama • Rochester, Minnesota • Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Feb 2, 2025 · Synced Jul 24, 2026, 5:51 AM EDT
Completed Not applicable Interventional Results available

Women Empowered to Live With Lupus Study

NCT02988661
View directory record Official record
Conditions
Lupus Erythematosus, Systemic
Interventions
Chronic Disease Self-management Program (CDSMP)
Behavioral
Lead sponsor
Emory University
Other
Eligibility
18 Years and older · Female only
Enrollment
699 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2025
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Dec 14, 2025 · Synced Jul 24, 2026, 5:51 AM EDT
Active, not recruiting Phase 3 Interventional

A Study to Learn About the Safety of Litifilimab (BIIB059) Injections and Whether They Can Improve Symptoms of Adult Participants Who Have Systemic Lupus Erythematosus

NCT04895241
View directory record Official record
Conditions
Lupus Erythematosus, Systemic
Interventions
Litifilimab, Placebo
Drug
Lead sponsor
Biogen
Industry
Eligibility
18 Years and older
Enrollment
548 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
53
States / cities
Homewood, Alabama • Beverly Hills, California • Los Angeles, California + 46 more
Source: ClinicalTrials.gov public record
Updated Feb 9, 2026 · Synced Jul 24, 2026, 5:51 AM EDT
Completed No phase listed Observational

Prospective Maternal Surveillance of SSA (Sjögren Syndrome A) Positive Pregnancies Using a Hand-held Fetal Heart Rate Monitor

NCT02920346
View directory record Official record
Conditions
Sjogren's Syndrome, Neonatal Systemic Lupus Erythematosus, Fetal Heart Block Complete
Interventions
Not listed
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years to 50 Years · Female only
Enrollment
700 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2020
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Jun 22, 2021 · Synced Jul 24, 2026, 5:51 AM EDT
Completed Phase 3 Interventional

Safety of Estrogens in Lupus: Birth Control Pills

NCT00000420
View directory record Official record
Conditions
Systemic Lupus Erythematosus
Interventions
Ortho-Novum 777
Drug
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years to 39 Years · Female only
Enrollment
350 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1997 – 2003
U.S. locations
15
States / cities
Los Angeles, California • Chicago, Illinois • Shreveport, Louisiana + 11 more
Source: ClinicalTrials.gov public record
Updated May 2, 2013 · Synced Jul 24, 2026, 5:51 AM EDT
Active, not recruiting Phase 2Phase 3 Interventional

A 2-Part Study to Learn Whether Litifilimab (BIIB059) Injections Can Improve Symptoms of Adult Participants Who Have Active Cutaneous Lupus Erythematosus

NCT05531565
View directory record Official record
Conditions
Subacute Cutaneous Lupus Erythematosus, Chronic Cutaneous Lupus Erythematosus
Interventions
Litifilimab, Placebo
Drug
Lead sponsor
Biogen
Industry
Eligibility
18 Years and older
Enrollment
450 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
62
States / cities
Anniston, Alabama • Birmingham, Alabama • Phoenix, Arizona + 52 more
Source: ClinicalTrials.gov public record
Updated Jul 15, 2026 · Synced Jul 24, 2026, 5:51 AM EDT
Completed Phase 2 Interventional Results available

JBT-101 in Systemic Lupus Erythematosus (SLE)

NCT03093402
View directory record Official record
Conditions
Systemic Lupus Erythematosus, SLE, Lupus
Interventions
JBT-101, Placebo
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 70 Years
Enrollment
109 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
16
States / cities
La Jolla, California • Los Angeles, California • San Francisco, California + 11 more
Source: ClinicalTrials.gov public record
Updated May 5, 2026 · Synced Jul 24, 2026, 5:51 AM EDT
Completed Phase 3 Interventional Results available

Belimumab Treatment Holiday and Treatment Re-start Study in Lupus Patients

NCT02119156
View directory record Official record
Conditions
Systemic Lupus Erythematosus
Interventions
Belimumab
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
3
States / cities
Los Angeles, California • Manhasset, New York • Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Jan 30, 2020 · Synced Jul 24, 2026, 5:51 AM EDT
Not listed No phase listed Observational Accepts healthy volunteers

Translation of a Diagnostic Test for Lupus Flare Prediction From Bench to Clinic

NCT04018222
View directory record Official record
Conditions
System; Lupus Erythematosus, Lupus Erythematosus, SLE, Lupus Flare
Interventions
Not listed
Lead sponsor
Progentec Diagnostics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
3
States / cities
Fort Lauderdale, Florida • Greenbelt, Maryland • Duncansville, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Sep 15, 2020 · Synced Jul 24, 2026, 5:51 AM EDT
Terminated Phase 3 Interventional Results available

A Study of Baricitinib in Participants With Systemic Lupus Erythematosus (SLE)

NCT03843125
View directory record Official record
Conditions
Systemic Lupus Erythematosus
Interventions
Baricitinib, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
1,147 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
61
States / cities
Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 51 more
Source: ClinicalTrials.gov public record
Updated May 15, 2023 · Synced Jul 24, 2026, 5:51 AM EDT
Completed Phase 4 Interventional Results available

Efficacy and Safety of Belimumab in Black Race Patients With Systemic Lupus Erythematosus (SLE)

NCT01632241
View directory record Official record
Conditions
Systemic Lupus Erythematosus
Interventions
Placebo plus standard therapy, Belimumab 10 mg/kg plus standard therapy, Standard therapy
Biological · Drug
Lead sponsor
Human Genome Sciences Inc., a GSK Company
Industry
Eligibility
18 Years and older
Enrollment
503 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2019
U.S. locations
64
States / cities
Birmingham, Alabama • Covina, California • La Palma, California + 49 more
Source: ClinicalTrials.gov public record
Updated Sep 7, 2021 · Synced Jul 24, 2026, 5:51 AM EDT
Not listed No phase listed Observational

Lupus Interval Monitoring to Manage Disease Flare and Enable Treatment Optimization

NCT03142412
View directory record Official record
Conditions
Systemic Lupus Erythematosus, Lupus, Lupus Erythematosus, Lupus Erythematosus, Systemic
Interventions
Not listed
Lead sponsor
DxTerity Diagnostics
Industry
Eligibility
18 Years and older
Enrollment
2,500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
1
States / cities
Compton, California
Source: ClinicalTrials.gov public record
Updated Jun 27, 2018 · Synced Jul 24, 2026, 5:51 AM EDT
Enrolling by invitation Phase 1Phase 2 Interventional

Electromagnetic Immunotherapy Mapping and Cytokine Forecasting Study (QSIT)

NCT07221565
View directory record Official record
Conditions
Systemic Lupus Erythematosus, Rheumatoid Arthritis, Multiple Sclerosis, Autoimmune Diseases, Chronic Inflammatory Syndromes, Immune Dysregulation
Interventions
Low-Frequency Electromagnetic Resonance Therapy (LF-EMR), Sham Resonance Device (Inactive Control), Low-Dose Naltrexone (LDN)
Device · Drug
Lead sponsor
Truway Health, Inc.
Industry
Eligibility
Not listed
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2034
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 21, 2026 · Synced Jul 24, 2026, 5:51 AM EDT
Terminated Phase 1 Interventional

Nonmyeloablative Allo Stem Cell Transplant for Severe Autoimmune Diseases

NCT00849745
View directory record Official record
Conditions
Systemic Lupus Erythematosus, Systemic Sclerosis
Interventions
Nonmyeloablative allogeneic stem cell transplant
Procedure
Lead sponsor
Duke University
Other
Eligibility
18 Years to 69 Years
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2015
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Jun 22, 2016 · Synced Jul 24, 2026, 5:51 AM EDT